Adjuvant Therapy for Renal Cell Carcinoma

Sumanta Kumar Pal, MD, assistant professor, genitourinary cancers, City of Hope, discusses adjuvant therapy for renal cell carcinoma (RCC).

Clinical Pearls:

• Adjuvant therapy is not currently a standard of care for localized RCC, however there are several studies that could put these agents into that disease space
• These studies are looking at VEGF- and mTOR-directed therapies
• Results of the ASSURE trial, which compared sunitinib, sorafenib and placebo in the adjuvant setting, will hopefully report out within the next 2-3 years
• Patients in the adjuvant setting may not tolerate the same doses as in the metastatic setting
• The EVEREST trial, which compares everolimus to placebo in the adjuvant setting, is about halfway accrued.
• Girentuximab, which targets CA9, was found to not have a significant impact on disease-free survival or overall survival